Cargando…

Illness Perception and Clinical Treatment Experiences in Patients with M. Maroteaux-Lamy (Mucopolysaccharidosis Type VI) and a Turkish Migration Background in Germany

INTRODUCTION: Mucopolysaccharidosis VI (MPS VI) is an inherited lysosomal storage disease caused by a mutation of the gene for arylsulfatase B (ASB). Of the thirty-one patients registered in Germany, almost fifty percent have a Turkish migration background. MPS VI is treated by enzyme replacement th...

Descripción completa

Detalles Bibliográficos
Autores principales: Dilger, Hansjörg, Leissner, Linn, Bosanska, Lenka, Lampe, Christina, Plöckinger, Ursula
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3691296/
https://www.ncbi.nlm.nih.gov/pubmed/23826140
http://dx.doi.org/10.1371/journal.pone.0066804
_version_ 1782274454470000640
author Dilger, Hansjörg
Leissner, Linn
Bosanska, Lenka
Lampe, Christina
Plöckinger, Ursula
author_facet Dilger, Hansjörg
Leissner, Linn
Bosanska, Lenka
Lampe, Christina
Plöckinger, Ursula
author_sort Dilger, Hansjörg
collection PubMed
description INTRODUCTION: Mucopolysaccharidosis VI (MPS VI) is an inherited lysosomal storage disease caused by a mutation of the gene for arylsulfatase B (ASB). Of the thirty-one patients registered in Germany, almost fifty percent have a Turkish migration background. MPS VI is treated by enzyme replacement therapy (ERT), which is time-consuming and expensive. METHODS: This interdisciplinary study explored the illness perceptions and clinical treatment experiences among ten MPS VI patients with a Turkish migration background in two centers for metabolic diseases (Berlin and Mainz, Germany). The clinical treatment situation was observed and semi-structured interviews were conducted with patients and health care personnel, in addition to participatory observation in four patients' everyday environments in Berlin. The data from the interviews, patient records, and personal field notes were encoded, cross-related, and analyzed. RESULTS: Patients' acknowledgement of the disease and coping strategies are influenced predominantly by the perception of their individual health status and the handling of the disease within their family. Patients' willingness to cooperate with treatment strategies is further modified by their knowledge of the disease and the relationships with their health care providers. In this analysis, cultural factors turned out to be marginally relevant. CONCLUSION: As with other chronic and debilitating diseases, effective treatment strategies have to reach beyond delivering medication. Health care providers need to strengthen the support for patients with a migration background. In this regard, they should respect the patients' cultural and social background and their personal perception of the disease and the therapy. Yet structural and social aspects (clinical setting, family and educational background) may be more crucial here than “cultural barriers.”
format Online
Article
Text
id pubmed-3691296
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-36912962013-07-03 Illness Perception and Clinical Treatment Experiences in Patients with M. Maroteaux-Lamy (Mucopolysaccharidosis Type VI) and a Turkish Migration Background in Germany Dilger, Hansjörg Leissner, Linn Bosanska, Lenka Lampe, Christina Plöckinger, Ursula PLoS One Research Article INTRODUCTION: Mucopolysaccharidosis VI (MPS VI) is an inherited lysosomal storage disease caused by a mutation of the gene for arylsulfatase B (ASB). Of the thirty-one patients registered in Germany, almost fifty percent have a Turkish migration background. MPS VI is treated by enzyme replacement therapy (ERT), which is time-consuming and expensive. METHODS: This interdisciplinary study explored the illness perceptions and clinical treatment experiences among ten MPS VI patients with a Turkish migration background in two centers for metabolic diseases (Berlin and Mainz, Germany). The clinical treatment situation was observed and semi-structured interviews were conducted with patients and health care personnel, in addition to participatory observation in four patients' everyday environments in Berlin. The data from the interviews, patient records, and personal field notes were encoded, cross-related, and analyzed. RESULTS: Patients' acknowledgement of the disease and coping strategies are influenced predominantly by the perception of their individual health status and the handling of the disease within their family. Patients' willingness to cooperate with treatment strategies is further modified by their knowledge of the disease and the relationships with their health care providers. In this analysis, cultural factors turned out to be marginally relevant. CONCLUSION: As with other chronic and debilitating diseases, effective treatment strategies have to reach beyond delivering medication. Health care providers need to strengthen the support for patients with a migration background. In this regard, they should respect the patients' cultural and social background and their personal perception of the disease and the therapy. Yet structural and social aspects (clinical setting, family and educational background) may be more crucial here than “cultural barriers.” Public Library of Science 2013-06-24 /pmc/articles/PMC3691296/ /pubmed/23826140 http://dx.doi.org/10.1371/journal.pone.0066804 Text en © 2013 Leissner et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Dilger, Hansjörg
Leissner, Linn
Bosanska, Lenka
Lampe, Christina
Plöckinger, Ursula
Illness Perception and Clinical Treatment Experiences in Patients with M. Maroteaux-Lamy (Mucopolysaccharidosis Type VI) and a Turkish Migration Background in Germany
title Illness Perception and Clinical Treatment Experiences in Patients with M. Maroteaux-Lamy (Mucopolysaccharidosis Type VI) and a Turkish Migration Background in Germany
title_full Illness Perception and Clinical Treatment Experiences in Patients with M. Maroteaux-Lamy (Mucopolysaccharidosis Type VI) and a Turkish Migration Background in Germany
title_fullStr Illness Perception and Clinical Treatment Experiences in Patients with M. Maroteaux-Lamy (Mucopolysaccharidosis Type VI) and a Turkish Migration Background in Germany
title_full_unstemmed Illness Perception and Clinical Treatment Experiences in Patients with M. Maroteaux-Lamy (Mucopolysaccharidosis Type VI) and a Turkish Migration Background in Germany
title_short Illness Perception and Clinical Treatment Experiences in Patients with M. Maroteaux-Lamy (Mucopolysaccharidosis Type VI) and a Turkish Migration Background in Germany
title_sort illness perception and clinical treatment experiences in patients with m. maroteaux-lamy (mucopolysaccharidosis type vi) and a turkish migration background in germany
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3691296/
https://www.ncbi.nlm.nih.gov/pubmed/23826140
http://dx.doi.org/10.1371/journal.pone.0066804
work_keys_str_mv AT dilgerhansjorg illnessperceptionandclinicaltreatmentexperiencesinpatientswithmmaroteauxlamymucopolysaccharidosistypeviandaturkishmigrationbackgroundingermany
AT leissnerlinn illnessperceptionandclinicaltreatmentexperiencesinpatientswithmmaroteauxlamymucopolysaccharidosistypeviandaturkishmigrationbackgroundingermany
AT bosanskalenka illnessperceptionandclinicaltreatmentexperiencesinpatientswithmmaroteauxlamymucopolysaccharidosistypeviandaturkishmigrationbackgroundingermany
AT lampechristina illnessperceptionandclinicaltreatmentexperiencesinpatientswithmmaroteauxlamymucopolysaccharidosistypeviandaturkishmigrationbackgroundingermany
AT plockingerursula illnessperceptionandclinicaltreatmentexperiencesinpatientswithmmaroteauxlamymucopolysaccharidosistypeviandaturkishmigrationbackgroundingermany